Adjuvant Alectinib Could Aid Disease-Free Survival in ALK-Positive NSCLC
A 76% lower risk was displayed with adjuvant alectinib compared to chemotherapy treatment for non–small cell lung cancer.
Roche Alectinib Levi Garraway National Cancer Institute Peter Maccallum Cancer Centre New England Journal Benjamin Solomon
Source: pharmacytimes.com